Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

RedChip will air sponsored interviews with Anixa Biosciences and Nexalin Technology on Bloomberg TV and CNBC on September 12-13. Anixa reported that its 35-patient Phase 1 breast-cancer vaccine trial met major endpoints, with no reported safety concerns and protocol-specified immune responses in 74% of participants, and is preparing a Phase 2 study. Nexalin highlighted its planned pivotal randomized, triple-blinded insomnia trial to support an FDA de novo submission for its non-invasive neurostimulation platform, but the release contains no new financial results or regulatory approvals.

Analysis

This is paid investor-relations distribution rather than an independently validating clinical, regulatory, or commercial event; the likely near-term effect is retail attention and transient liquidity, not a defensible change in intrinsic value. ANIX and NXL should be treated as high-volatility microcap event vehicles over the next 1-3 sessions, particularly given weekend broadcast timing, with elevated risk of a sell-the-attention reversal once incremental promotional flow ends.

For ANIX, the valuation-relevant transition remains from immunogenicity/safety to controlled evidence of clinical benefit. The Phase 2 design, enrollment pace, cash runway, and any efficacy-linked endpoint—not publicity—will determine whether the breast-vaccine platform receives a material probability-of-success re-rating over the next 6-18 months. A meaningful risk is that immune response proves poorly correlated with recurrence or pathologic response, while multiple development programs can raise future financing needs and dilute shareholders before value-inflecting data.

NXL has a potentially more investable operating leverage path if it can establish FDA clearance and convert home-use neurostimulation into reimbursed recurring revenue, but that remains contingent on pivotal insomnia data, de novo review, manufacturing execution, and clinical adoption. The market may underappreciate reimbursement friction: a direct-to-consumer or remote-monitoring model can generate engagement without proving durable unit economics. The thesis is falsified by a pivotal miss, an FDA request that materially expands the evidence package, or a cash raise at a discount before commercialization metrics emerge.

Key Decisions for Investors

• No fundamental long initiated solely on the broadcast; avoid chasing ANIX or NXL in the first 1-2 trading sessions after the program. Treat unusually high volume without an SEC-filed clinical, regulatory, or financing update as a liquidity event rather than confirmation.
• For ANIX, establish an alert for Phase 2 protocol details, funded enrollment milestones, and cash runway disclosures. Consider a small long only after financing risk is quantifiable and the study specifies a clinically meaningful efficacy endpoint; exit on a material runway deterioration or guidance toward near-term dilutive capital.
• For NXL, monitor the pivotal insomnia trial's enrollment completion and FDA pre-submission/de novo timeline over the next 3-12 months. A long is conditional on independently disclosed trial design and funding sufficient through review; size as binary regulatory exposure, with a hard thesis stop on pivotal-data delay or an equity issuance below market.
• For short-term trading only, if either name gaps materially on promotional volume and fails to hold the opening-range low, consider a tightly risk-controlled fade rather than a directional investment. Cover on a new primary-source catalyst, such as filed clinical data, FDA correspondence, or financing on favorable terms.